Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Proximity Health Solutions, in collaboration with Biogen, announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE ...

If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors has ...

US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...